Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BBP 631

Next Previous
Search
Drug Profile

BBP 631

Alternative Names: BBP-631

Latest Information Update: 13 Sep 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Life Technologies Corporation
  • Developer Adrenas Therapeutics
  • Class Gene therapies
  • Mechanism of Action Gene transference; Steroid 21 hydroxylase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Congenital adrenal hyperplasia
  • New Molecular Entity No
  • Available For Licensing Yes - Congenital adrenal hyperplasia

Highest Development Phases

  • Phase I/II Congenital adrenal hyperplasia

Most Recent Events

  • 10 Sep 2024 BBP 631 is available for licensing as of 10 Sep 2024.
  • 10 Sep 2024 Pharmacodynamics and adverse event data from the phase I/II ADventure trial in Congenital adrenal hyperplasia released by BridgeBio Pharma
  • 03 Oct 2023 BridgeBio Pharma and Resilience entered into a strategic collaboration agreement to manufacture and advance BBP 631 for Congenital adrenal hyperplasia

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top